Flumetasone + clioquinol


Generic Medicine Info
Contraindications
Perforation of the tympanic membrane, disorders associated w/ therapy-resistant secondary infection, iodine sensitivity, primary bacterial, viral, or fungal infection of the outer ear. Childn <2 yr.
Special Precautions
Patient w/ thyroid abnormalities. Childn. Pregnancy and lactation. Patient Counselling This drug may cause discolouration of skin, hair, and cloth. Avoid application to the eye.
Adverse Reactions
Endocrine: Adrenal suppression (prolonged use). Ophthalmologic: Increased risk of cataract. Dermatologic: Skin atrophy, telangiectasia, purpura, striae, dermatitis, skin depigmentation, hair colour changes, hypertrichosis, application site burning or irritation, rash, pruritus, impaired healing. Immunologic: Hypersensitivity, manifestations of bacterial, viral, or fungal infection.
ATC Classification
P01AA02 - clioquinol ; Belongs to the class of hydroxyquinoline derivatives antiprotozoals. Used in the treatment amoebiasis and other protozoal diseases.
D07XB01 - flumetasone ; Belongs to the class of moderately potent (group II) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
S02AA05 - clioquinol ; Belongs to the class of antiinfectives used in the treatment of ear infections.
G01AC02 - clioquinol ; Belongs to the class of quinolone derivative antiinfectives. Used in the treatment of gynecological infections.
D09AA10 - clioquinol ; Belongs to the class of ointment dressings with antiinfectives.
D07AB03 - flumetasone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
D08AH30 - clioquinol ; Belongs to the class of quinolone derivative antiseptics. Used in the treatment of dermatological diseases.
Disclaimer: This information is independently developed by CIMS based on flumetasone + clioquinol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in